WP
IBRX icon

Woodline Partners’s ImmunityBio IBRX Stock Holding History

Woodline Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
2,500,189
-947,157
-27% -$7.17M 0.07% 347
2026
Q1 		$26.4M Buy
3,447,346
+806
+0% +$5.52K 0.1% 277
2025
Q4 		$6.82M Sell
3,446,540
-1,851,185
-35% -$4.19M 0.03% 555
2025
Q3 		$13M Buy
5,297,725
+1,851,854
+54% +$4.77M 0.06% 377
2025
Q2 		$9.1M Buy
3,445,871
+774
+0% +$2.08K 0.05% 449
2025
Q1 		$10.4M Buy
3,445,097
+2,657
+0.1% +$8.05K 0.07% 354
2024
Q4 		$8.81M Buy
3,442,440
+3,002,622
+683% +$12.5M 0.06% 376
2024
Q3 		$1.64M Buy
439,818
+1,975
+0.5% +$9.14K 0.01% 486
2024
Q2 		$2.77M Buy
+437,843
New +$2.89M 0.03% 391

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Woodline Partners's IBRX Position: Q2 2026 in Review

Woodline Partners reduced its ImmunityBio (IBRX) stake by 27% in Q2 2026, selling an estimated $7.17M and leaving 2,500,189 shares worth $21.9M. The position accounts for 0.07% of the portfolio, ranked #347.

Woodline Partners first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $26.4M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Woodline Partners held 2,500,189 shares of ImmunityBio worth $21.9M as of Q2 2026.
  • Woodline Partners sold 947,157 ImmunityBio shares in Q2 2026, an estimated $7.17M.
  • ImmunityBio made up 0.07% of Woodline Partners's portfolio in Q2 2026, its #347 holding.
  • Woodline Partners first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
  • Woodline Partners's ImmunityBio position peaked at $26.4M in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.